Patents by Inventor Lex M. Cowsert

Lex M. Cowsert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6187586
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-3. Methods of using these compounds for modulation of Akt-3 expression and for treatment of diseases associated with expression of Akt-3 are provided.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Richard A. Roth
  • Patent number: 6184212
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 6, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert
  • Patent number: 6180353
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of daxx. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding daxx. Methods of using these compounds for modulation of daxx expression and for treatment of diseases associated with expression of daxx are provided.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: January 30, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Lex M. Cowsert
  • Patent number: 6177273
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Integrin-linked kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Integrin-linked kinase. Methods of using these compounds for modulation of Integrin-linked kinase expression and for treatment of diseases associated with expression of Integrin-linked kinase are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: January 23, 2001
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6174870
    Abstract: Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide or oligonucleotide analog is provided which is hybridizable with a messenger RNA from a papillomavirus. The oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, E6 or E6-7 messenger RNAs.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: January 16, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 6171860
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of RANK. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RANK. Methods of using these compounds for inhibition of RANK expression and for treatment of diseases associated with expression of RANK are provided.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: January 9, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Patent number: 6168950
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: January 2, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Lex M. Cowsert
  • Patent number: 6165789
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hnRNP A1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hnRNP A1. Methods of using these compounds for modulation of hnRNP A1 expression and for treatment of diseases associated with expression of hnRNP A1 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6165786
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of Nucleolin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Nucleolin. Methods of using these compounds for modulation of Nucleolin expression and for treatment of diseases associated with expression of Nucleolin are provided.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6165788
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Eric E. Swayze, Lex M. Cowsert
  • Patent number: 6165728
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of nck-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding nck-2. Methods of using these compounds for modulation of nck-2 expression and for treatment of diseases associated with expression of nck-2 are provided.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Patent number: 6165790
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of PI3 kinase p55 gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p55 gamma. Methods of using these compounds for inhibition of PI3 kinase p55 gamma expression and for treatment of diseases associated with expression of PI3 kinase p55 gamma are provided.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Alexander H. Borchers, Donna T. Ward, Lex M. Cowsert
  • Patent number: 6159697
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad7. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad7. Methods of using these compounds for modulation of Smad7 expression and for treatment of diseases associated with expression of Smad7 are provided.
    Type: Grant
    Filed: January 9, 2000
    Date of Patent: December 12, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6156571
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-3. Methods of using these compounds for modulation of SRC-3 expression and for treatment of diseases associated with expression of SRC-3 are provided.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: December 5, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6150162
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD44. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD44. Methods of using these compounds for modulation of CD44 expression and for treatment of diseases associated with expression of CD44 are provided.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: November 21, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6140125
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bc1-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bc1-6. Methods of using these compounds for modulation of bc1-6 expression and for treatment of diseases associated with expression of bc1-6 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Patent number: 6140126
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Y-box binding protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Y-box binding protein 1. Methods of using these compounds for modulation of Y-box binding protein 1 expression and for treatment of diseases associated with expression of Y-box binding protein 1 are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6133032
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 beta. Methods of using these compounds for modulation of PI3 kinase p110 beta expression and for treatment of diseases associated with expression of PI3 kinase p110 beta are provided.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceutical Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6130088
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Telomeric Repeat Binding Factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Telomeric Repeat Binding Factor 1. Methods of using these compounds for modulation of Telomeric Repeat Binding Factor 1 expression and for treatment of diseases associated with expression of Telomeric Repeat Binding Factor 1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: October 10, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6124272
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PDK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PDK-1. Methods of using these compounds for modulation of PDK-1 expression and for treatment of diseases associated with expression of PDK-1 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceutical Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert